Loading...

CTOR CITIUS ONCOLOGY INC Company Mergers 8-K Filing

CTS

CTR

CITIUS ONCOLOGY INC

(CTOR)

2025 8-K

Quarterly Results Report

Warrant Inducement

Product Shipment Announcement

Nasdaq Compliance Notice

Commercial Update

Trial Results Positive

Positive Trial Results

Earnings Announcement

Financial Results Announcement

Stock Offering Announcement

New Product Launch

Stock Incentive Plan

Corporate Update

Stock Warrants Issued

Equity Offering Details

Registration Update

Equity Offerings

Follow-on Offerings

Product Expansion

Financial Statements

Delisting due to Non-Compli...

Agreement Amendment

Quarterly Results

J-Code Announcement

Product Launch Progress

Strategic Review

Earnings Announcement

Clinical Trial Results

Payment Deferral

Business Combination

Business Combination

Stock Incentive Plan Approval

Extension of Business Combi...

Extension of Business Combi...

Redemption Payments

Extension of Business Combi...

Extension of Business Combi...

Meeting and Merger Approval

Merger Agreement

Extension of Business Combi...

Debt Restructuring

External Links:

Citius Oncology, Inc. has amended its agreement with Eisai regarding milestone payments for the product LYMPHIR, with a total obligation of $5,900,000 due upon FDA approval in August 2024, and additional development costs of $8,233,209.77 incurred, with a payment schedule established for 2025.

AI Assistant

CITIUS ONCOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.